Latest profit margin for Fennec Pharmaceuticals: -17.21% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2026
Trailing 12 months ending Mar 2026
The latest profit margin for FENC is -17.21% as of March 2026. That compares with -45.52% in the prior-year period — up 62.2% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Fennec Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Over the past year, FENC's profit margin moved from -45.52% to -17.21% — a 62.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fennec Pharmaceuticals's valuation or profitability profile.
Against Healthcare companies, FENC currently prints -17.21% for profit margin, while the sector average sits near 15.58%. That is roughly 210.4% below the sector mean. Large gaps often invite a closer look at Fennec Pharmaceuticals's growth, margins, and balance sheet.
Profit Margin shows how effectively Fennec Pharmaceuticals converts resources into returns. At -17.21%, FENC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -45.52% in the prior-year period — up 62.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting FENC's profit margin (-17.21%), review year-over-year change from -45.52%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.